ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-12J9107
Home | Market Reports | Health| Health Conditions
Global Irritable Bowel Syndrome with Diarrhea IBS D Drugs Market Outlook 2022
BUY CHAPTERS

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2024

Code: QYRE-Auto-12J9107
Report
January 2024
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bausch Health
Allergan plc
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal pharms
Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ 1388.1 million in 2023 and is anticipated to reach US$ 2851.1 million by 2030, witnessing a CAGR of 10.7% during the forecast period 2024-2030.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.

Report Scope

The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Sales Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Sales Channel, and by regions.
Market Segmentation

Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report

Report Metric Details
Report Name Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
Accounted market size in 2023 US$ 1388.1 million
Forecasted market size in 2030 US$ 2851.1 million
CAGR 10.7%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • XIFAXAN
  • Viberzi
  • Lotronex
  • Other
Segment by Sales Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Sales Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Sales Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market growing?

Ans: The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market witnessing a CAGR of 10.7% during the forecast period 2024-2030.

What is the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market size in 2030?

Ans: The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market size in 2030 will be US$ 2851.1 million.

Who are the main players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market report?

Ans: The main players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market are Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma

What are the Type segmentation covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market report?

Ans: The Types covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market report are XIFAXAN, Viberzi, Lotronex, Other

1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 XIFAXAN
1.2.3 Viberzi
1.2.4 Lotronex
1.2.5 Other
1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Sales Channel
1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Sales Channel: (2024-2030)
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2030
1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2030
1.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application
2.7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
2.7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue
2.7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario by Region
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2019-2030
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2019-2024
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2025-2030
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2019-2030
3.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2019-2024
3.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2025-2030
3.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.4.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2030)
3.4.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.5.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2030)
3.5.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.7.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2030)
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2025-2030)
4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2019-2030)
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2019-2024)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2025-2030)
4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2019-2030)
5 Segment by Sales Channel
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2030)
5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024)
5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2025-2030)
5.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2030)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2019-2030)
5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2019-2024)
5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2025-2030)
5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2019-2030)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2019-2030)
6 Key Companies Profiled
6.1 Bausch Health
6.1.1 Bausch Health Corporation Information
6.1.2 Bausch Health Description and Business Overview
6.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.1.5 Bausch Health Recent Developments/Updates
6.2 Allergan
6.2.1 Allergan Corporation Information
6.2.2 Allergan Description and Business Overview
6.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.2.5 Allergan Recent Developments/Updates
6.3 Sebela Pharmaceuticals
6.3.1 Sebela Pharmaceuticals Corporation Information
6.3.2 Sebela Pharmaceuticals Description and Business Overview
6.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.3.5 Sebela Pharmaceuticals Recent Developments/Updates
6.4 Astellas Pharmaceuticals
6.4.1 Astellas Pharmaceuticals Corporation Information
6.4.2 Astellas Pharmaceuticals Description and Business Overview
6.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.4.5 Astellas Pharmaceuticals Recent Developments/Updates
6.5 Amneal Pharms
6.5.1 Amneal Pharms Corporation Information
6.5.2 Amneal Pharms Description and Business Overview
6.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.5.5 Amneal Pharms Recent Developments/Updates
6.6 Pharscin Pharma
6.6.1 Pharscin Pharma Corporation Information
6.6.2 Pharscin Pharma Description and Business Overview
6.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.6.5 Pharscin Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Chain Analysis
7.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Marketing
7.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels
7.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
7.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
8 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
8.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bausch Health
Allergan plc
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal pharms
Pharscin Pharma
List of Tables
    Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value Comparison by Sales Channel (2024-2030) & (US$ Million)
    Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application
    Table 12. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019-2024) & (K Units)
    Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2019-2024)
    Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2025-2030) & (K Units)
    Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2025-2030)
    Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2019-2024)
    Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2025-2030)
    Table 25. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
    Table 27. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2025-2030) & (K Units)
    Table 28. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Type (2019-2024)
    Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Type (2025-2030)
    Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
    Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2025-2030)
    Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2019-2024)
    Table 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2025-2030)
    Table 58. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2019-2024)
    Table 59. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2025-2030)
    Table 60. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Sales Channel (2019-2024)
    Table 61. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Sales Channel (2025-2030)
    Table 62. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
    Table 63. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2025-2030)
    Table 64. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Sales Channel (2019-2024)
    Table 65. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Sales Channel (2025-2030)
    Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2019-2024)
    Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2025-2030)
    Table 68. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2019-2024)
    Table 69. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2025-2030)
    Table 70. Bausch Health Corporation Information
    Table 71. Bausch Health Description and Business Overview
    Table 72. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 73. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 74. Bausch Health Recent Developments/Updates
    Table 75. Allergan Corporation Information
    Table 76. Allergan Description and Business Overview
    Table 77. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 78. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 79. Allergan Recent Developments/Updates
    Table 80. Sebela Pharmaceuticals Corporation Information
    Table 81. Sebela Pharmaceuticals Description and Business Overview
    Table 82. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 83. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 84. Sebela Pharmaceuticals Recent Developments/Updates
    Table 85. Astellas Pharmaceuticals Corporation Information
    Table 86. Astellas Pharmaceuticals Description and Business Overview
    Table 87. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 88. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 89. Astellas Pharmaceuticals Recent Developments/Updates
    Table 90. Amneal Pharms Corporation Information
    Table 91. Amneal Pharms Description and Business Overview
    Table 92. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 93. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 94. Amneal Pharms Recent Developments/Updates
    Table 95. Pharscin Pharma Corporation Information
    Table 96. Pharscin Pharma Description and Business Overview
    Table 97. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 98. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 99. Pharscin Pharma Recent Developments/Updates
    Table 100. Key Raw Materials Lists
    Table 101. Raw Materials Key Suppliers Lists
    Table 102. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
    Table 103. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
    Table 104. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
    Table 105. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
    Table 106. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
    Table 107. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
    Table 108. Research Programs/Design for This Report
    Table 109. Key Data Information from Secondary Sources
    Table 110. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2023 & 2030
    Figure 4. XIFAXAN Product Picture
    Figure 5. Viberzi Product Picture
    Figure 6. Lotronex Product Picture
    Figure 7. Other Product Picture
    Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value Comparison by Sales Channel (2024-2030) & (US$ Million)
    Figure 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Sales Channel in 2023 & 2030
    Figure 10. Hospitals Pharmacy
    Figure 11. Retail Pharmacy
    Figure 12. Other
    Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (2019-2030) & (US$ Million)
    Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2019-2030) & (K Units)
    Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) & (2019-2030)
    Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
    Figure 18. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers in 2023
    Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2023
    Figure 20. The Global 5 and 10 Largest Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players: Market Share by Revenue in 2023
    Figure 21. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 23. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2030)
    Figure 24. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2030)
    Figure 25. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2030)
    Figure 28. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2030)
    Figure 29. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2019-2030)
    Figure 35. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2019-2030)
    Figure 36. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2030)
    Figure 46. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2030)
    Figure 47. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2030)
    Figure 51. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2030)
    Figure 52. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. Global Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2019-2030)
    Figure 56. Global Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2019-2030)
    Figure 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2019-2030)
    Figure 58. Global Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2019-2030)
    Figure 59. Global Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2019-2030)
    Figure 60. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2019-2030)
    Figure 61. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain
    Figure 62. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Process
    Figure 63. Channels of Distribution (Direct Vs Distribution)
    Figure 64. Distributors Profiles
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Respiratory Infection Diagnostic Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-39D3651
Wed Apr 17 00:00:00 UTC 2024

Add to Cart

Global Internal Neuromodulation Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-24F2529
Wed Apr 17 00:00:00 UTC 2024

Add to Cart

Global Colon Cancer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-31C5944
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-10J13802
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions